PYPD (PolyPid) Short Interest

View and export this data going back to 2020. Start your Free Trial

What is PolyPid Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of PolyPid's Short Interest

For the Biotechnology subindustry, PolyPid's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PolyPid's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PolyPid's Short Interest distribution charts can be found below:

* The bar in red indicates where PolyPid's Short Interest falls into.

Save Embed

;

Save Embed

;

PolyPid Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PolyPid Ltd (NAS:PYPD) » Definitions » Short Interest

Comparable Companies

Traded in Other Exchanges

N/A

Address

18 Hasivim Street, P.O Box 7126, Petach Tikva, ISR, 495376

Website

https://www.polypid.com

PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.